Business
‘We do not have capacity’ to make the Novavax vaccine, says CSL – Sydney Morning Herald
Biotechnology giant CSL has dashed speculation it could make the Novavax coronavirus vaccine onshore at the same time as it produces AstraZeneca’s product.
“At the request of government we have carefully considered our ability to simultaneously manufacture the Novavax vaccine, but unfortunately we do not have the capacity or capability to manufacture two COVID-19 vaccines involving live viruses,” the spokeswoman said.
“CSL remains fully focussed on production of the AstraZeneca vaccine and anticipates that the first locally produced doses of the vaccine will be ready in the second quarter of 2021, subject to regulatory approval.”
A purchasing agreement…
-
General24 hours agoMelbourne lawyer fled Australia with $1.2m after filing for bankruptcy, court case alleges
-
Noosa News20 hours agoMaroons name Gehamat Shibasaki for State of Origin debut against Blues, Josh Papali’i returns
-
Business20 hours agoShould I sell my loss-making stocks today?
-
Business21 hours agoCan the Xero share price deliver a 17% return after the US acquisition?